|
Cardiovascular diseases constitute an important public health problem as they are the main cause of morbidity and mortality in the world. Therefore, there is a growing need for more effective and safe pharmacotherapeutic treatments.
However, although physicians prescribe drugs based on the pharmacological characteristics of the drug and the likelihood of obtaining clinically reproducible results, many drugs are effective in only 25-60% of patients.
In this sense, Pharmacogenomics, through the study of genetic Osicent 80 mg (Osimertinib) variants of proteins involved in the pharmacokinetics and pharmacodynamics of medications, seeks to maximize their effectiveness and safety.
Cardiovascular drugs act on the functioning of the heart and blood circulation. The success of modern medicine is partly the result of effective drug treatment. A well-known fact is that individuals respond differently to drug therapy and that no medication is 100% effective in all patients.
Consequently, the range of response to a pharmacological treatment is diverse, since some individuals can obtain the expected effects, while others do not obtain a therapeutic result and may even experience adverse effects.
It is very important that the patient knows the main beneficial effects, the form and frequency of administration, the correct dose and possible side effects. Only in this way will you be able to collaborate with the doctor to achieve an effective and well-tolerated treatment.
|
|